8-K
filed April 30, 2026, 7:59 PM ET
ticker WDC
CIK 0000106040
earnings
confidence high
sentiment positive
materiality 0.90
WD Q3FY26 revenue up 45% YoY to $3.34B; GAAP EPS $8.20, non-GAAP $2.72; dividend up 20%
WESTERN DIGITAL CORP
2026-Q3 EPS reported
$16.05
revenue$9,172,000,000
- Revenue $3.34B, up 45% YoY; GAAP diluted EPS $8.20, non-GAAP diluted EPS $2.72.
- GAAP gross margin 50.2% (up 1040 bps YoY); non-GAAP gross margin 50.5%.
- Cash from operations $1.12B, free cash flow $978M.
- Q4FY26 revenue guidance ~$3.65B; non-GAAP gross margin 51%-52%; non-GAAP EPS ~$3.25.
- Quarterly dividend increased 20% to $0.15 per share.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001628280-26-028878
- form_type
- 8-K
- ticker
- WDC
- cik
- 0000106040
- company_name
- WESTERN DIGITAL CORP
- filed_at
- 2026-04-30T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:31.890789+00:00
- generated_at
- 2026-05-15T00:31:35.933470+00:00
- sec_items
- ["2.02", "9.01"]
- event_type
- earnings
- sentiment
- positive
- materiality_score
- 0.9
- calibrated_materiality_score
- 0.9
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001628280-26-028878
- json_url
- https://secwatch.observer/filing/0001628280-26-028878.json
- markdown_url
- https://secwatch.observer/filing/0001628280-26-028878.md
- text_url
- https://secwatch.observer/filing/0001628280-26-028878.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/106040/000162828026028878/0001628280-26-028878-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/106040/000162828026028878/wdc-20260430.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
HPE
HPE Q2 FY26: record revenue $10.7B (+40%), raises FY26 guidance, introduces FY27 framework
Hewlett Packard Enterprise Co
June 1, 2026, 4:09 PM ET
earnings
Items 1.01, 2.02, 5.02, 7.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
GAAP Q3FY26 Q2FY26 Q3FY25 Q/Q Y/Y Revenue $3,337 $3,017 $2,294 +11% +45% Gross Margin 50.2% 45.7% 39.8% +450 bps +1040 bps Operating Income $1,190 $908 $760 +31% +57% Operating Margin 35.7% 30.1% 33.1% +560 bps +260 bps Diluted Net Income Attributable to Common Shareholders $3,172 $1,802 $755 +76% +320% Diluted Net Income Per Common Share $8.20 $4.73 $2.11 +73% +289%
Comparable filing
gross margin, and non-GAAP diluted net EPS, as well as its highest-ever free cash flow generation for a second quarter. Second Quarter Fiscal 2026 Financial Results • Revenue : $10.7 billion, up 40% from the prior-year period • Gross margins : ◦ GAAP of 36.5%, up 810 basis points from the prior-year period and up 60 basis points sequentially ◦ Non-GAAP (1) of 36.9%,
Filing page
SEC filing
CRDO
Credo Q4 revenue $437M (+157% YoY); guides Q1 $465-475M; CEO awarded 1.44M performance-based RSUs
Credo Technology Group Holding Ltd
June 1, 2026, 4:08 PM ET
earnings
Items 2.02, 5.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
GAAP Q3FY26 Q2FY26 Q3FY25 Q/Q Y/Y Revenue $3,337 $3,017 $2,294 +11% +45% Gross Margin 50.2% 45.7% 39.8% +450 bps +1040 bps Operating Income $1,190 $908 $760 +31% +57% Operating Margin 35.7% 30.1% 33.1% +560 bps +260 bps Diluted Net Income Attributable to Common Shareholders $3,172 $1,802 $755 +76% +320% Diluted Net Income Per Common Share $8.20 $4.73 $2.11 +73% +289%
Comparable filing
On June 1, 2026, Credo Technology Group Holding Ltd (the "Company") issued a press release announcing its financial results for the fiscal year ended May 2, 2026.
Filing page
SEC filing
ACH
Accendra Health Q1 revenue $627.8M, adj. EBITDA $58.4M; >$1.5B debt optimization
ACCENDRA HEALTH INC/VA/
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 7.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
GAAP Q3FY26 Q2FY26 Q3FY25 Q/Q Y/Y Revenue $3,337 $3,017 $2,294 +11% +45% Gross Margin 50.2% 45.7% 39.8% +450 bps +1040 bps Operating Income $1,190 $908 $760 +31% +57% Operating Margin 35.7% 30.1% 33.1% +560 bps +260 bps Diluted Net Income Attributable to Common Shareholders $3,172 $1,802 $755 +76% +320% Diluted Net Income Per Common Share $8.20 $4.73 $2.11 +73% +289%
Comparable filing
Commission this morning. Details on First Quarter 2026 Results First Quarter Results (1) ($ in millions, except per share data) 1Q26 1Q25 Net Revenue $ 627.8 $ 673.9 Loss from continuing operations, net of tax, GAAP $ (6.5) $ (3.8) Adj. net (loss) income from continuing operations, Non-GAAP $ (3.1) $ 23.2
Filing page
SEC filing
LQDA
Liquidia Q1 2026 net income $53M vs $38M loss YoY; YUTREPIA sales $130M
Liquidia Corp
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 8.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
GAAP Q3FY26 Q2FY26 Q3FY25 Q/Q Y/Y Revenue $3,337 $3,017 $2,294 +11% +45% Gross Margin 50.2% 45.7% 39.8% +450 bps +1040 bps Operating Income $1,190 $908 $760 +31% +57% Operating Margin 35.7% 30.1% 33.1% +560 bps +260 bps Diluted Net Income Attributable to Common Shareholders $3,172 $1,802 $755 +76% +320% Diluted Net Income Per Common Share $8.20 $4.73 $2.11 +73% +289%
Comparable filing
First Quarter 2026 Financial Results YUTREPIA sales led to the company’s third consecutive quarter of profitability with net income of $52.9 million and positive non-GAAP adjusted EBITDA of $71.2 million in the first quarter of 2026. Cash and cash equivalents totaled $222.8 million as of March 31, 2026, compared to $190.7 million as of December 31, 2025. Product sales, net, were $129.9 million for the three months ended March 31, 2026.
Filing page
SEC filing
TH
Target Hospitality Q1 revenue up 4% but net loss widens to $13M; announces $750M AI infrastructure contract
Target Hospitality Corp.
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
GAAP Q3FY26 Q2FY26 Q3FY25 Q/Q Y/Y Revenue $3,337 $3,017 $2,294 +11% +45% Gross Margin 50.2% 45.7% 39.8% +450 bps +1040 bps Operating Income $1,190 $908 $760 +31% +57% Operating Margin 35.7% 30.1% 33.1% +560 bps +260 bps Diluted Net Income Attributable to Common Shareholders $3,172 $1,802 $755 +76% +320% Diluted Net Income Per Common Share $8.20 $4.73 $2.11 +73% +289%
Comparable filing
today reported results for the three months ended March 31, 2026. Financial Highlights for the quarter ended March 31, 2026 ● Revenue of $72.8 million. ● Net loss of ($13.0) million. ● Basic and diluted loss per share of $0.13 . ● Adjusted EBITDA (1) of $9.9 million. ● Net Cash Provided by Operating Activities of $7.0 million and Discretionary Cash
Filing page
SEC filing
FSK
FSK posts Q1 GAAP loss of $1.57/sh, NAV falls to $18.83; announces $150M preferred, tender, buyback
FS KKR Capital Corp
May 11, 2026, 7:59 PM ET
earnings
Items 1.01, 2.02, 7.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
GAAP Q3FY26 Q2FY26 Q3FY25 Q/Q Y/Y Revenue $3,337 $3,017 $2,294 +11% +45% Gross Margin 50.2% 45.7% 39.8% +450 bps +1040 bps Operating Income $1,190 $908 $760 +31% +57% Operating Margin 35.7% 30.1% 33.1% +560 bps +260 bps Diluted Net Income Attributable to Common Shareholders $3,172 $1,802 $755 +76% +320% Diluted Net Income Per Common Share $8.20 $4.73 $2.11 +73% +289%
Comparable filing
Earnings (Loss) per share of ($1.57), compared to Earnings (Loss) per share of ($0.41) for the quarter ended December 31, 2025
Filing page
SEC filing
APGE
Apogee reports Q1 loss of $74.1M; $1.3B cash; zumilokibart Phase 3 AD on track
Apogee Therapeutics, Inc.
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
GAAP Q3FY26 Q2FY26 Q3FY25 Q/Q Y/Y Revenue $3,337 $3,017 $2,294 +11% +45% Gross Margin 50.2% 45.7% 39.8% +450 bps +1040 bps Operating Income $1,190 $908 $760 +31% +57% Operating Margin 35.7% 30.1% 33.1% +560 bps +260 bps Diluted Net Income Attributable to Common Shareholders $3,172 $1,802 $755 +76% +320% Diluted Net Income Per Common Share $8.20 $4.73 $2.11 +73% +289%
Comparable filing
On May 11, 2026, Apogee Therapeutics, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the quarter ended March 31, 2026 (the “Earnings Press Release”).
Filing page
SEC filing
COCH
Envoy Medical completes pivotal trial enrollment for fully implanted cochlear implant; raises $30M
Envoy Medical, Inc.
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
GAAP Q3FY26 Q2FY26 Q3FY25 Q/Q Y/Y Revenue $3,337 $3,017 $2,294 +11% +45% Gross Margin 50.2% 45.7% 39.8% +450 bps +1040 bps Operating Income $1,190 $908 $760 +31% +57% Operating Margin 35.7% 30.1% 33.1% +560 bps +260 bps Diluted Net Income Attributable to Common Shareholders $3,172 $1,802 $755 +76% +320% Diluted Net Income Per Common Share $8.20 $4.73 $2.11 +73% +289%
Comparable filing
Net Revenue was $39 for the three months ended March 31, 2026.
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.